MSB 0.30% $1.69 mesoblast limited

Nature publication, page-10

  1. 2,496 Posts.
    lightbulb Created with Sketch. 649
    That's my take, more over when you add Remestemcell-L to the available treatments, we would only be treating those with the high MAP. As we already know that these patients have a 90% chance of not responding to steroids. Remestemcell-L will become a first in line treatment in combination with steroids. When we finally get to test the product on adults we do not need to use jak inhibitors, they would be used as a salvage treatment in those remaining few that do not respond to our therapy.

    I would also think it highly likely that MAP biomarkers would be used as a quality attributed between batches.
    As a final check on the product for release we would only need to treat 4 patients to have a 90% confidence that the product was highly effective.

    Good luck all

watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $1.093B
Open High Low Value Volume
$1.68 $1.71 $1.67 $2.147M 1.273M

Buyers (Bids)

No. Vol. Price($)
4 20893 $1.69

Sellers (Offers)

Price($) Vol. No.
$1.69 5000 1
View Market Depth
Last trade - 16.10pm 22/10/2021 (20 minute delay) ?
0.005 ( 0.89 %)
Open High Low Volume
$1.68 $1.71 $1.67 160036
Last updated 15.59pm 22/10/2021 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.